Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

MYC rearrangements with immunoglobulin genes as an independent prognostic factor of progression-free survival in newly diagnosed patients

View Full Paper
Ask AI
Bookmark
Share

Authors

CUCaitlin UnkenholzJCJorge ContrerasRPRoger Pearse

Discussion

Loading...

Member takes

Overview

Findings reveal immunoglobulin gene involvement predicts shorter progression-free survival in myeloma, suggesting MYC rearrangements are significant biomarkers.

Key Points

  • This research aims to assess the clinical impact of MYC rearrangements involving immunoglobulin genes on progression-free survival in multiple myeloma.
  • Used MMRF-NGS cohort to assess MYC rearrangement prevalence and impact on PFS.
  • Conducted FISH analysis in 133 patients from the WCM-FISH cohort to identify MYC alterations.
  • Utilized genomic proximity mapping to evaluate MYC alteration cases in patients from a prospective trial.
  • MYC rearrangements were found in 25.6% of patients from the MMRF-NGS cohort.
  • Patients with immunoglobulin-related MYC rearrangements had decreased PFS of 25.4 months compared to 42.2 months for other configurations.
  • In multivariable models, MYC rearrangements remained significantly associated with inferior PFS.

Cite This Study

Unkenholz et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d407https://doi.org/10.1182/blood-2025-361
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MYC rearrangement improves the predictive efficacy of the double-hit model in newly diagnosed multiple myeloma2026
  2. 2Myc rearrangement redefines the stratification of high‐risk multiple myeloma2024 · 4 citations
  3. 3P31 | PROGNOSTIC IMPACT OF INTERPHASE FISH IN MULTIPLE MYELOMA: SINGLE-CENTER IRISH EXPERIENCE2026
  4. 4Beyond FISH: CMA detects 8p-, xq+, and y- as markers of early post-transplant progression in myeloma2025
  5. 5Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups.2025